Last reviewed · How we verify

NCT04339322: COVID-19

Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt

Status unknown Last updated 9 April 2020
What this trial tests

trial testing Follow up in Characteristics Diseases in 200 participants. Status unknown.

Timeline
1 May 2020
Primary endpoint
30 July 2020
30 July 2020

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date1 May 2020
Primary completion30 July 2020
Estimated completion30 July 2020

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Characteristics Diseases or Outcome, Fatal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The World Health Organization (WHO) has recently declared coronavirus disease 2019 (Covid-19) a public health emergency of international concern. Egypt is one of the countries that has been infected by Covid-19. The characteristics of clinical presentation, laboratory and radiological data are not yet studied. Outcomes of covid-19 in Egypt also have not been described yet.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Follow up

Trials testing the same drug.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04339322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing